Cardiff Oncology Analyst Price Targets - Benzinga

SPY752.16−0.29%QQQ681.66−0.53%BTC/USD76,887.83−0.59%DIA515.40−0.32%GLD360.39+0.32%TLT81.29+0.22%

Premium Services

Premium Services

Cardiff Oncology Inc

CRDFNASDAQ

Trade with Public

Trade with Public

$0.8631

0.01882.23%

Last update: Nov 3, 4:08 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Cardiff Oncology Analyst Price Targets - Benzinga

Cardiff Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cardiff Oncology (CRDF).

Price Target Range — 10 Quarters

Analyst Consensus — 7 Analysts

3Buy

4Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$9Upside to Avg. PT+904.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	HC Wainwright & Co.	Robert Burns	Upgrade	Neutral→Buy	$9
Aug 12, 2026	William Blair	Andy Hsieh	Downgrade	Outperform→Market Perform	—
Jun 3, 2026	Craig-Hallum	Albert Lowe	Downgrade	Buy→Hold	$10→$2
Jun 1, 2026	TD Cowen	Marc Frahm	Downgrade	Buy→Hold	—
Jun 1, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Feb 25, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$10→$6
Jan 28, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
Aug 6, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$18→$10
Jul 8, 2025	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$19
Jun 24, 2025	Jefferies	Maury Raycroft	Initiate	Hold	$4
May 9, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$17→$18
Feb 28, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$13→$17
Dec 13, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$7→$10
Nov 8, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$14→$13
Sep 6, 2024	Craig-Hallum	Albert Lowe	Initiate	Buy	$8
May 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$14
Mar 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$12→$14
Mar 1, 2024	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$5→$7

Analyst Ratings News

PRO
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target

HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.

Benzinga Newsdesk

PRO
William Blair Downgrades Cardiff Oncology to Market Perform

William Blair analyst Andy Hsieh downgrades Cardiff Oncology (NASDAQ:CRDF) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2

Craig-Hallum analyst Albert Lowe downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold and lowers the price target from $10 to $2.

Benzinga Newsdesk

PRO
TD Cowen Downgrades Cardiff Oncology to Hold

TD Cowen analyst Marc Frahm downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold.

Benzinga Newsdesk

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Cardiff Oncology to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Neutral.

Benzinga Newsdesk